Evolving role of bone biomarkers in castration-resistant prostate cancer.
The preferential metastasis of prostate cancer cells to bone disrupts the process of bone remodeling and results in lesions that cause significant pain and patient morbidity. Although prostate-specific antigen (PSA) is an established biomarker in prostate cancer, it provides only limited information relating to bone metastases and the treatment of metastatic bone disease with bisphosphonates or novel noncytotoxic targeted or biological agents that may provide clinical benefits without affecting PSA levels. As bone metastases develop, factors derived from bone metabolism are released into blood and urine, including N- and C-terminal peptide fragments of type 1 collagen and bone-specific alkaline phosphatase, which represent potentially useful biomarkers for monitoring metastatic bone disease. A number of clinical trials have investigated these bone biomarkers with respect to their diagnostic, prognostic, and predictive values. Results suggest that higher levels of bone biomarkers are associated with an increased risk of skeletal-related events and/or death. As a result of these findings, bone biomarkers are now being increasingly used as study end points, particularly in studies investigating novel agents with putative bone effects. Data from prospective clinical trials are needed to validate the use of bone biomarkers and to confirm that marker levels provide additional information beyond traditional methods of response evaluation for patients with metastatic prostate cancer.
Brown
Janet E
JE
Cancer Research UK Clinical Centre, University of Leeds, Leeds, UK. j.e.brown@leeds.ac.uk
Sim
Sheryl
S
D014408:Biomarkers, Tumor / Q000097:blood / Q000378:metabolism / Q000502:physiology* / Q000652:urine; D001859:Bone Neoplasms / Q000175:diagnosis / Q000378:metabolism / Q000556:secondary; D001842:Bone and Bones / Q000378:metabolism*; D002277:Carcinoma / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D006801:Humans; D008297:Male; D008954:Models, Biological; D058990:Molecular Targeted Therapy / Q000379:methods / Q000639:trends; D009919:Orchiectomy / Q000379:methods; D011237:Predictive Value of Tests; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D017211:Treatment Failure
D014408:Biomarkers, Tumor
Osteoporos Int. 2011 Jan;22(1):369-70
20306021
Nat Clin Pract Oncol. 2005 Oct;2(10):504-17; quiz 1 p following 533
16205770
Clin Cancer Res. 2008 Oct 1;14(19):6302-9
18829513
Proteomics. 2005 Aug;5(13):3329-42
16052622
J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68
12359855
Cancer. 2007 Oct 15;110(8):1860-7
17763372
Clin Genitourin Cancer. 2007 Sep;5(6):390-6
17956712
Calcif Tissue Int. 1991 Dec;49(6):421-6
1818768
Clin Chem. 1994 Nov;40(11 Pt 1):2022-5
7955372
Br J Cancer. 2000 Feb;82(4):858-64
10732759
Clin Chem. 1996 Jun;42(6 Pt 1):947-54
8665688
Clin Chem. 1999 Aug;45(8 Pt 2):1359-68
10430819
Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6213s-6216s
17062703
J Clin Oncol. 1998 May;16(5):1835-43
9586898
Cancer Res. 2005 Oct 15;65(20):9185-9
16230377
Clin Chem. 1990 Jul;36(7):1328-32
2372946
Acta Oncol. 2006;45(2):216-7
16546871
N Engl J Med. 2004 Apr 15;350(16):1655-64
15084698
Expert Rev Proteomics. 2007 Jun;4(3):371-8
17552921
Clin Chem. 2009 Apr;55(4):765-73
19233911
Ann Oncol. 2008 Sep;19 Suppl 7:vii91-5
18790987
N Engl J Med. 2009 Mar 26;360(13):1320-8
19297566
Cancer Treat Rev. 2008 Nov;34(7):629-39
18579314
Clin Cancer Res. 2008 Oct 1;14(19):6270-6
18829508
Prostate. 2009 May 1;69(6):624-32
19143027
Mol Cancer Res. 2009 Apr;7(4):476-88
19372577
J Natl Cancer Inst. 2005 Jan 5;97(1):59-69
15632381
Cancer. 2000 Jun 15;88(12 Suppl):2989-94
10898342
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
19474385
Int J Cancer. 2004 Sep 20;111(5):783-91
15252851
Cancer Res. 2009 Jan 1;69(1):151-60
19117998
Cancer. 2007 Mar 15;109(6):1090-6
17311345
Oncologist. 2009 Aug;14(8):816-27
19684076
Expert Rev Proteomics. 2005 Oct;2(5):693-703
16209649
J Clin Oncol. 2003 Feb 15;21(4):679-89
12586806
J Bone Miner Res. 1992 Nov;7(11):1251-8
1466251
Cancer. 2007 Nov 1;110(9):1959-66
17886253
J Clin Oncol. 2005 Aug 1;23(22):4925-35
15983391
Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3361-7
16740758
Hum Pathol. 2000 May;31(5):578-83
10836297
J Bone Miner Res. 1994 Oct;9(10):1643-9
7817812
Clin Chem. 2001 Mar;47(3):597-600
11238321
Lancet Oncol. 2009 Mar;10(3):233-9
19213602
Clin Cancer Res. 2001 Dec;7(12):4060-6
11751502
Cancer. 2002 Sep 1;95(5):1028-36
12209687
Prostate. 2006 Apr 1;66(5):503-13
16372331
J Clin Oncol. 2007 Nov 20;25(33):5313-8
17925542
Cancer. 2003 Feb 1;97(3 Suppl):779-84
12548575
J Natl Cancer Inst. 1998 Jul 1;90(13):1000-8
9665149
Clin Cancer Res. 2007 Jun 1;13(11):3244-9
17545529
Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):32-8
16434583
Clin Chem. 1996 Nov;42(11):1796-804
8906079
J Bone Miner Res. 2010 Mar;25(3):463-71
19775203
Cancer Res. 1997 Dec 15;57(24):5517-20
9407961
Lancet Oncol. 2007 Jul;8(7):587-94
17544845
Clin Cancer Res. 2008 Jan 1;14(1):209-14
18172272
Eur Urol. 2005 Dec;48(6):1031-41
16054748
Calcif Tissue Int. 1998 Aug;63(2):102-6
9685512
N Engl J Med. 2004 Oct 7;351(15):1513-20
15470214
Cancer. 2000 Jun 15;88(12 Suppl):2961-78
10898340
J Clin Oncol. 2009 May 20;27(15):2450-6
19380444
Eur Urol. 2009 May;55(5):1112-23
19042080
J Bone Miner Res. 2003 May;18(5):859-67
12733725
J Clin Endocrinol Metab. 2003 Nov;88(11):5059-75
14602728
Cancer. 2008 Jul 1;113(1):193-201
18459173
Anticancer Res. 2009 Feb;29(2):671-3
19331219
Cancer. 2006 Aug 1;107(3):530-5
16804927
Support Cancer Ther. 2005 Jul 1;2(4):234-40
18628179
Clin Cancer Res. 2007 Dec 1;13(23):7053-8
18056182
J Clin Oncol. 2009 May 20;27(15):2429-35
19364971
Ann Oncol. 2009 May;20(5):913-20
19403935
BJU Int. 2001 Mar;87(4):348-51
11251528
Acta Oncol. 2007;46(2):221-9
17453373
Cancer Treat Rev. 2001 Jun;27(3):165-76
11417967
Eur Urol. 2007 Nov;52(5):1381-7
17321667
J Clin Endocrinol Metab. 1990 Aug;71(2):442-51
2380339
Cancer. 2006 Jul 15;107(2):289-98
16752412
Bone. 1996 Aug;19(2):157-63
8853860
Ann Oncol. 2007 Mar;18(3):581-92
17287242
J Urol. 2007 Sep;178(3 Pt 1):849-53; discussion 853; quiz 1129
17631330
Int J Clin Pract. 2009 Jan;63(1):19-26
19125989
J Urol. 2009 Aug;182(2):509-15; discussion 515-6
19524963
Clin Chem. 2001 Apr;47(4):747-9
11274028
N Engl J Med. 2004 Oct 7;351(15):1502-12
15470213
Curr Opin Urol. 2008 May;18(3):303-8
18382240
Cancer. 1997 Oct 15;80(8 Suppl):1588-94
9362426
Clin Chem. 1993 Apr;39(4):635-40
8472358
Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10954-9
12941866
J Clin Oncol. 2008 Mar 1;26(7):1148-59
18309951
Bone. 1995 Apr;16(4):461-7
7605707
J Urol. 2003 Mar;169(3):1143-9
12576870
Clin Chem. 1987 Apr;33(4):458-62
3829376
Anticancer Res. 2005 Mar-Apr;25(2B):1457-63
15865105
Osteoporos Int. 2000;11 Suppl 6:S18-29
11193236
Ann Clin Biochem. 2000 Jul;37 ( Pt 4):432-46
10902858
Leukemia. 2009 May;23(5):994-7
19092851
Cancer Treat Rev. 2001 Jun;27(3):187-92; discussion 193-6
11417970
Clin Chem. 1995 Nov;41(11):1560-6
7586543
Ann Oncol. 2005 Apr;16(4):579-84
15734776
Invest New Drugs. 2011 Feb;29(1):118-25
19763400
Dis Markers. 2006;22(4):245-55
17124346
Mol Cancer Ther. 2007 Oct;6(10):2609-17
17938257
J Natl Cancer Inst. 2004 Jun 2;96(11):879-82
15173273
Cancer Biomark. 2006;2(6):249-58
17264396
J Clin Oncol. 2009 May 20;27(15):2436-42
19364960
Anal Biochem. 2003 Jul 15;318(2):204-11
12814623
Clin Cancer Res. 2009 Dec 1;15(23):7421-8
19920114
J Clin Oncol. 2007 Sep 1;25(25):3965-70
17761981
Clin Chem. 2005 Apr;51(4):695-707
15695329
J Med Chem. 2004 Dec 30;47(27):6658-61
15615512
Anticancer Drugs. 2009 Mar;20(3):179-84
19396016
Clin Chem. 1996 Oct;42(10):1639-44
8855148
Leukemia. 2009 Mar;23(3):590-4
18784745
J Clin Oncol. 2009 Apr 1;27(10):1564-71
19237632
J Bone Miner Res. 2010 Mar;25(3):440-6
19653815
Clin Chem. 1997 Nov;43(11):2076-82
9365391
Ann Oncol. 2010 Sep;21(9):1864-1869
20181574
Cancer Res. 2008 May 1;68(9):3323-33
18451159